Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

NCT03180619 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
124
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Gilead Sciences